Chronic Liver Diseases Therapeutics Market, by Treatment Type, by Disease Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The liver is the largest solid internal organ of the body which performs various roles that include creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper functioning of the liver are obesity, excessive alcohol consumption, and genetic disorder. The treatment option available to treat liver diseases includes antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period.

For instance, Primary Sclerosing Cholangitis (PSC), is a chronic disease in which the bile duct inside and outside the liver become inflamed and scarred, eventually narrowed and blocked, subsequently, bile builds up in the liver and causes liver damage. According to National Institute of Health Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the U.S, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population respectively.

Key features of the study:

• This report provides an in-depth analysis of the global chronic liver diseases therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic liver diseases therapeutics market

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:

• Antiviral Drugs
• Immunosuppressants
• Vaccines
• Immunoglobulins
• Corticosteroids
• Targeted Therapy
• Chemotherapy

Global Chronic Liver Diseases Therapeutics Market, By Disease Type:

• Hepatitis
• Autoimmune Diseases
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Cancer
• Genetic Disorder
• Others

Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Chronic Liver Diseases Therapeutics Market, By Region:

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa

Company Profiles

• Astellas Pharma Inc.
• Company Overview
• Material Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline Plc
• Hoffmann-La Roche Ltd
• Merck & Co. Inc
• Novartis AG
• Sanofi S.A
• Pfizer Inc
• Takeda Pharmaceutical
• Valeant Pharmaceuticals
• Watson Pharmaceuticals
• Theratechnologies Inc
• Alnylam Pharmaceuticals, Inc
• Protagonist Therapeutics, Inc
• Dicerna Pharmaceuticals, Inc
• Endo International
• Provectus Biopharmaceuticals Inc
• MAX BioPharma, Inc.